Barnaby Pickering
Reporter
Barnaby lives and works in Yorkshire. Having graduated from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.
Latest From Barnaby Pickering
Execs On The Move, January 2023: Spun-Off GE Healthcare Names Board, Officers
An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.
Axogen, Dario Health, Biobeat, Immunexpress All Weigh In On 2022 And What Will Succeed In 2023
Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.
Snapshot: January Highlights
A selection of articles you may have missed from January 2023, covering the FDA's approach to gene therapies and their long-term implications, the rise (and possible fall) of Chinese companies' efforts in drug development and the ongoing consideration of the 'E' in ESG.
Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical
Sequana Medical is simultaneously developing both drug and device treatments for fluid overloads in the body. Medtech Insight spoke to the company’s CEO about their trials and the challenges of raising cash in 2023.
Contrast Agent, Liquid Biopsy Tool Or Treatment? Earli Might Deliver All Three At Once
The company has developed a technology that uses engineered DNA to reprogram cancer cells, forcing them to produce substances that could be used to help image, detect or even destroy them.
Pneumowave Breathes Easier In Its Fight Against Opioid Deaths After Completing £7.5m Raise
The Glasgow-based company has completed a large series A round to further develop its technology, which can be used to help save patients’ lives in the event of opioid overdose. Medtech Insight spoke to the Scottish National Investment Bank, one of the main investors, about the deal and its altruistic view of investment.